A Risk-Scoring Model for the Prediction of Endometrial Cancer among Symptomatic Postmenopausal Women with Endometrial Thickness > 4 mm

Table 1

Univariate analysis comparing clinical variables and endometrial assessment between women with (𝑛=72) or without (𝑛=552) endometrial cancer.

Variables	Women with endometrial cancer 𝑛 (%)	Women without endometrial cancer 𝑛 (%)	P value
Age (years)*	69 (66–71)	59 (55–65)	<0.0001^a
Age at menarche (years)*	12 (12-13)	12 (11–13)	0.29^a
Age at menopause (years)*	52 (50–53)	52 (50–53)	0.86^a
Time since menopause (years)*	17 (17-18)	7 (4–14)	<0.0001^a
BMI*	28 (25–31)	28 (27–31)	0.16^a
Parity			0.22^b
Nulligravid	12 (16.6)	132 (23.9)
Parous	60 (83.4)	420 (76.1)
HRT use			0.0001^b
Yes	0 (0)	108 (19.5)
No	72 (100)	444 (80.5)
Vaginal bleeding			<0.0001^b
Single episode	24 (33.3)	348 (63.0)
Recurrent episode	48 (66.7)	204 (37.0)
Hypertension			<0.0001^b
Yes	48 (66.7)	208 (37.6)
No	24 (33.3)	344 (62.4)
Diabetes			0.88^b
Yes	12 (16.6)	84 (15.2)
No	60 (83.4)	468 (84.8)
Tamoxifen			0.097^c
Current users	0 (0)	0 (0)
Past users	0 (0)	24 (4.3)
Never users	72 (100)	528 (95.7)
Anticoagulant use			0.53^b
Yes	18 (25.0)	116 (21.1)
No	54 (75.0)	436 (78.9)
Breast cancer			0.097^c
Yes	0 (0)	24 (4.3)
No	72 (100)	528 (95.7)
Endometrial echogenicity			<0.0001^b
Uniform	0 (0)	200 (36.2)
Nonuniform	72 (100)	352 (63.8)
Endometrial thickness (mm)*	11 (9–13)	8 (6–10)	<0.0001^a

∗The values are expressed by median and interquartile range. aUsing Mann-Whitney test; busing Chi-square analysis; cusing Fisher’s exact test; BMI: body mass index; HRT: hormone replacement therapy.